CoChat

Controversies in the Pathogenesis, Diagnosis and Treatment of PCOS: Focus on Insulin Resistance, Inflammation, and Hyperandrogenism

Open access
Armanini, Decio, Boscaro, Marco, Bordin, Luciana, Sabbadin, Chiara · 2022 · International Journal of Molecular Sciences

The DOI matches its Crossref record; 84 of the 85 references it cites were found in a registry or an index; 11 of the 90 sources its claims cite were checked for support.

Abstract

Polycystic ovary syndrome (PCOS) is a heterogeneous and extremely common disease with symptoms that vary with the age of the patient, typically characterized by hyperandrogenism, chronic oligo-anovulation, and/or several metabolic disorders. The syndrome includes various phenotypes, and the pathogenesis is multifactorial, often involving insulin resistance. This feature is closely related to ovarian dysfunction, inflammation, hyperandrogenism, and metabolic disorders, which characterize and complicate the syndrome. Therapy currently considers both lifestyle improvements and medications, and must be tailored on a case-by-case basis. To date, the published studies have not arrived at a definition of the most suitable therapy for each individual case and many of the drugs used are still off-label. In this review, we discuss some controversial diagnostic and therapeutic aspects of PCOS, such as the role of insulin resistance, inflammation, and hyperandrogenism. We also evaluated the advantages and disadvantages of contraceptive therapy and antiandrogens.

Overview

CoChat Summary

TL;DR

This review discusses controversies in the pathogenesis, diagnosis, and treatment of polycystic ovary syndrome (PCOS), focusing on insulin resistance, inflammation, and hyperandrogenism. It argues that therapy must be individualized and that, apart from combined oral contraceptives (COCs), most drugs used for PCOS remain off-label, with larger and longer-term studies needed.

Key findings

  • PCOS prevalence varies by diagnostic criteria: 4–8% by NIH/NICHD criteria and approximately 18% by Rotterdam criteria; the Rotterdam criteria are endorsed by a recent international evidence-based guideline.
  • Insulin resistance is common in PCOS, worsened by hyperandrogenism-related adipose tissue accumulation, and compensatory hyperinsulinemia stimulates ovarian theca androgen production and decreases hepatic SHBG synthesis, increasing total and free androgens.
  • Chronic low-grade inflammation is associated with increased white blood cell count, CRP, IL-6, IL-18, monocyte chemoattractant protein-1, and macrophage inflammatory protein-1; aldosterone and the aldosterone/renin ratio are often increased in PCOS and may accentuate inflammation and metabolic/cardiovascular disorders.
  • Treatment should start with lifestyle improvement; metformin, inositols (with a MYO:DCI ratio of 40:1 described as most effective), GLP-1 receptor agonists, and SGLT2 inhibitors are discussed, while COCs and antiandrogens have benefits and risks; spironolactone is preferred among antiandrogens because it also has anti-inflammatory action.

Methods

  • Narrative review of published literature on PCOS pathogenesis, diagnosis, and treatment, with emphasis on insulin resistance, inflammation, and hyperandrogenism.
  • The paper synthesizes prior studies and guidelines, including diagnostic criteria, PCOS phenotypes A–D, androgen measurement issues, insulin resistance assessment, and therapeutic options.
  • No primary data collection, new patient sample, or systematic meta-analysis is described.

Limitations

  • Stated: many PCOS drugs are off-label; more randomized controlled trials and long-term studies are needed; larger samples are needed to evaluate new therapies and inflammation in adipose tissue; microbiome role requires further study; studies of third-generation contraceptives are short-term, discordant, and often limited in patient numbers.
  • Evident from the text: as a narrative review, it does not report a systematic search strategy, formal risk-of-bias assessment, or new empirical data, so conclusions rely on interpretation of cited literature.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3390/ijms23084110

Cites

84 of 84 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Figures

Figure 1 Pathophysiology and potential therapeutic targets of PCOS.
Figure 1 Pathophysiology and potential therapeutic targets of PCOS.CC BY · PubMed Central

Verification

Claims the paper makes

9 Valid · 7 Not valid · 66 Not checked · 16 Own results and interpretations

48 more claims · 1 with their cited sources checked

Create a free account to see all 98 claims and to verify the 79 references still open.

See all claims — free account
  • It may state two separate claims as one. 39
  • Probably not a substantial claim. 8

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 more claim about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 84 references

Cited by

Items 301–324 of 324

Metadata

Authors
Armanini, D., Boscaro, M., Bordin, L., & Sabbadin, C.
Affiliations
University of Padua (IT)
Corresponding author
Armanini, Decio
Venue
International Journal of Molecular Sciences
Publisher
MDPI AG
Published
2022-04-08
Volume
23
Issue
8
Pages
4110
ISSN
1422-0067 (ISSN-L)
OpenAlex
W4224247712
Cited by
324
References
85
Citations by year
2026: 66 · 2025: 105 · 2024: 82 · 2023: 58 · 2022: 13
FWCI
10.39
Type
journal article
Language
en
Open access
Locations
  • International Journal of Molecular Sciences (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
  • Health Sciences › Medicine › Reproductive Medicine › Endometriosis Research and Treatment
  • Health Sciences › Medicine › Reproductive Medicine › Reproductive Biology and Fertility
Keywords
polycystic ovary syndrome, insulin resistance, inflammation, hyperandrogenism, PCOS pathogenesis, PCOS diagnosis, PCOS treatment, androgen receptor antagonists, metabolic disorders, oligoanovulation, PCOS phenotypes
MeSH terms
Female, Humans, Inflammation, Insulin Resistance, Metabolic Diseases, Polycystic Ovary Syndrome, Hyperandrogenism

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.